Ticker: MRNA | Published: 2026-09-22
Melanoma Data Fuels Rally
Strong melanoma study results presented at a major oncology conference pushed the stock to a 52-week high, and the low volatility with normal volume suggests the market absorbed the news quickly and is now trading steadily higher rather than churning.
Sources: https://finance.yahoo.com/healthcare/articles/mrna-hits-52-week-high-125700042.html, https://finan